Literature DB >> 15754775

An adipocentric view of liver fibrosis and cirrhosis.

Jiin-Haur Chuang1, Pei-Wen Wang, Min-Hong Tai.   

Abstract

Liver fibrosis is the consequence of chronic or repeated liver injury caused by hepatotoxic agents like alcohol and viruses, as well as immune and congenital metabolic disorders. Nonalcoholic fatty liver disease (NAFLD), caused by obesity and abnormal lipid metabolism, may be the latest known cause of liver fibrosis and cirrhosis. Furthermore, NAFLD with obesity can provide a terrain in which alcoholic and viral liver diseases, such as chronic hepatitis C, are prone to cause liver cirrhosis. Insulin, insulin-like growth factor (IGF)-1, peroxisome proliferator-activated receptors (PPARs), leptin, adiponectin, and preadipocyte factor-1/delta-like1 (Pref-1/dlk1) are hormones, growth factors, nuclear receptors, and cytokines that are actively involved in lipid metabolism. They share common target cells important in liver fibrosis, i.e., hepatic stellate cells (HSCs). Activation of HSCs is known to initiate and perpetuate liver fibrosis. Insulin and IGF-1 stimulate HSC activation and collagen production in vitro. However, IGF-1 alleviates liver fibrosis in vivo. Ligands of PPARy inhibit HSC activation and collagen synthesis in vivo and in vitro, and are helpful in decreasing liver fibrosis. But ligands of PPARbeta enhance proliferation of HSCs. Leptin is profibrogenic, and liver fibrosis is decreased in leptin- or leptin receptor-deficient mice. Adiponectin is, on the contrary, anti-fibrogenic. Extensive liver fibrosis may develop in adiponectin-knockout mice and is alleviated by administration of recombinant adiponectin. Pref-1/dlkl is implicated in fibrogenesis of the liver through its modulation of HSCs. The use of such biologically active molecules in lipid metabolism as ligands of PPARgamma and adiponectin might not help slim down a patient on the whole, but can potentially be used to halt the progression of liver fibrosis. Weight reduction, a strategy for controlling obesity and metabolic syndromes, may also be a tool for decreasing NAFLD and alleviating liver cirrhosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15754775

Source DB:  PubMed          Journal:  Chang Gung Med J        ISSN: 2072-0939


  12 in total

1.  Serum retinol binding protein 4 and clinical outcome in postoperative biliary atresia.

Authors:  Maneerat Chayanupatkul; Sittisak Honsawek; Voranush Chongsrisawat; Linda Vimolket; Yong Poovorawan
Journal:  Hepatol Int       Date:  2011-03-06       Impact factor: 6.047

2.  Hepatic differentiation and maturation of human embryonic stem cells cultured in a perfused three-dimensional bioreactor.

Authors:  Louise Sivertsson; Jane Synnergren; Janne Jensen; Petter Björquist; Magnus Ingelman-Sundberg
Journal:  Stem Cells Dev       Date:  2012-11-02       Impact factor: 3.272

3.  An herbal formula, CGX, exerts hepatotherapeutic effects on dimethylnitrosamine-induced chronic liver injury model in rats.

Authors:  Jang-Woo Shin; Jin-Young Son; Se-Mi Oh; Seung-Hyun Han; Jing-Hua Wang; Jung-Hyo Cho; Chong-Kwan Cho; Hwa-Seung Yoo; Yeon-Weol Lee; Myong-Min Lee; Xiao-Ping Hu; Chang-Gue Son
Journal:  World J Gastroenterol       Date:  2006-10-14       Impact factor: 5.742

Review 4.  Leptin in the field of hepatic fibrosis: a pivotal or an incidental player?

Authors:  Sotirios K Bethanis; Stamatios E Theocharis
Journal:  Dig Dis Sci       Date:  2006-10       Impact factor: 3.199

5.  Senescence Marker Protein 30: Functional and Structural Insights to its Unknown Physiological Function.

Authors:  Stephanie H Scott; Brian J Bahnson
Journal:  Biomol Concepts       Date:  2012-07-24

Review 6.  Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver.

Authors:  Scott L Friedman
Journal:  Physiol Rev       Date:  2008-01       Impact factor: 37.312

7.  Serum level of adiponectin correlated with gender and genotype in patients with chronic hepatitis C.

Authors:  Qing-Hua Meng; Zhong-Hui Duan; Zun-Hui Lin; Hong-Wei Yu; Juan Li; Ya Liu
Journal:  Dig Dis Sci       Date:  2008-09-05       Impact factor: 3.199

8.  Clinical Predictors of Liver Fibrosis Presence and Progression in Human Immunodeficiency Virus-Associated Nonalcoholic Fatty Liver Disease.

Authors:  Lindsay T Fourman; Takara L Stanley; Isabel Zheng; Chelsea S Pan; Meghan N Feldpausch; Julia Purdy; Julia Aepfelbacher; Colleen Buckless; Andrew Tsao; Kathleen E Corey; Raymond T Chung; Martin Torriani; David E Kleiner; Colleen M Hadigan; Steven K Grinspoon
Journal:  Clin Infect Dis       Date:  2021-06-15       Impact factor: 9.079

9.  Serum adiponectin and transient elastography as non-invasive markers for postoperative biliary atresia.

Authors:  Sittisak Honsawek; Maneerat Chayanupatkul; Voranush Chongsrisawat; Apiradee Theamboonlers; Kesmanee Praianantathavorn; Wanvisa Udomsinprasert; Paisarn Vejchapipat; Yong Poovorawan
Journal:  BMC Gastroenterol       Date:  2011-02-28       Impact factor: 3.067

10.  Morphological and metabolic determinants of nonalcoholic fatty liver disease in obese youth: a pilot study.

Authors:  Paula A Monteiro; Jorge Mota; Loreana S Silveira; Suziane U Cayres; Bárbara de Moura M Antunes; Romulo Araujo Fernandes; Ismael F Freitas
Journal:  BMC Res Notes       Date:  2013-03-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.